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Background: Nesiritide is continued to be used in patients with acute heart failure. This study aims to investigate the effects of nesiritide on 
diuretic response early after admission for acute heart failure.
methods: Diuretic response, defined as weight loss per 40 mg furosemide or equivalent, was examined from hospital admission to 48 
hours in 4,379 patients from the ASCEND-HF trial.
results: Mean diuretic response was -0.42 kg/40 mg furosemide [IQR -1.0, -0.05]. Poor responders had lower blood pressure, more 
frequent diabetes, chronic use of loop diuretics, poorer baseline renal function, and lower urine output (all P<0.01). Nesiritide was not 
associated with diuretic response (P=0.987). Good diuretic response was independently associated with a significant decreased risk in 
30 day all cause mortality or rehospitalization (OR 0.44 [0.29-0.65] for highest vs lowest quintile, P<0.001) and 30 day cardiac death or 
rehospitalization (OR 0.52 [0.36-0.75] for highest vs lowest quintile, P<0.001). As a sensitivity analysis diuretic response based on urine 
output per 40 mg furosemide from admission to 24 hours was investigated, identifying an association with worse renal function and no 
significant association with nesiritide treatment (P=0.110).
conclusion:  Poor diuretic response early in hospitalization is associated with low blood pressure, renal impairment, low urine output and 
an increased risk of death or rehospitalization early after discharge. Nesiritide had a neutral effect on diuretic response.
Table: Survival analysis per quintiles of diuretic response
30 Day All Cause Mortality or Rehospitalization* 30 Day Cardiac Death or Rehospitalization*
Univariate Multivariate Univariate Multivariate
Diuretic Response 
Quintile OR (95% CI) P-Value OR (95% CI) P-Value OR (95% CI) P-Value OR (95% CI) P-Value
Quintile 1:
(-6.0 to -1.2 kg/dose)
0.29
(0.20, 0.42) <0.001
0.44
(0.29, 0.65) <0.001
0.34
(0.25, 0.48) <0.001
0.52
(0.36, 0.75) <0.001
Quintile 2:
(-1.2 to -0.6 kg/dose)
0.45
(0.33, 0.63) <0.001
0.56
(0.39, 0.79) 0.001
0.50
(0.37, 0.67) <0.001
0.63
(0.46, 0.87) 0.005
Quintile 3:
(-0.6 to -0.3 kg/dose)
0.48
(0.35, 0.66) <0.001
0.55
(0.39, 0.77) <0.001
0.48
(0.35, 0.65) <0.001
0.57
(0.41, 0.79) <0.001
Quintile 4:
(-0.3 to 0 kg/dose)
0.58
(0.44, 0.78) <0.001
0.66
(0.48, 0.90) 0.009
0.61
(0.46, 0.80) <0.001
0.70
(0.52, 0.94) 0.017
Quintile 5:
(0 to 2.7 kg/dose)
1.0 
(Reference) Ref
1.0 
(Reference) Ref
1.0 
(Reference) Ref
1.0 
(Reference) Ref
* = model adjusted for: age, BUN, cerebrovascular disease, creatinine, history of depression, dyspnea, hospitalization for heart failure 
in last year, sodium, elevated jvp, systolic blood pressure (baseline), copd, type of diuretic given (Forsemide, Torsemide, Bumetanide), 
baseline weight, gender, race, orthopnea, peripheral edema, history of diabetes, hyperlipidemia, diuretic use chronically before qualifying 
event, potassium, and change in systolic blood pressure (baseline to 24hrs).
